ABSTRACT

OBJECTIVE

It is aimed that, to investigate the effect of estradiol valerate and dienogest combination, which is used as a hormone replacement therapy (HRT) regimen on hemostatic parameters and activated protein C resistance in healthy postmenopausal women.

MATERIAL-METHOD

Fifty seven women received HRT treatment in four month period. The placebo group consisted of 50 women. In the HRT group 10.5% (6/57), and in the placebo group 4% (2/50) were heterozigot of FV Leiden mutation. Hemostatic parameters were investigated in only non-mutation women, to avoid potential effects of FV Leiden mutation on activated protein C.

RESULTS

Although these changes did not reach statistical significance, a comparison of hemostatic parameters for both groups showed that in the study group (receiving 2mgEV/2mgDNG) FV and Protein C levels were increased, and FVIII levels were decreased compared to the placebo group. There were also no significant differences in FVII and free protein S levels. Multiple logistic regression analysis was performed to determine the association of (2mgEV/2mgDNG) treatment with FV, FVII, FVIII, protein C, free protein S and activated protein C sensitivity rate. There was no significant effect of these independent variables on activated protein C sensitivity rate (p>0.05).

CONCLUSION

Combination of estradiol valerate and dienogest has no effect on activated protein C sensitivity ratios. Hormone replacement therapy does not cause acquired activated protein C resistance (p>0.05).